Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1
EV-104
A Study of Intravesical Enfortumab Vedotin For Treatment of Patients With Non-muscle Invasive Bladder Cancer (NMIBC)
- NCT05014139 ↗
- Terminated
- Astellas Pharma Global Development, Inc.
- Standard
We haven't built an HCP commentary report on EV-104 (intravesical enfortumab vedotin in non-muscle invasive bladder cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on EV-104 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 6 | |
| YouTube | 4 | |
| Podcasts | 2 |
The trial
ClinicalTrials.gov- Official title
- A Study of Intravesical Enfortumab Vedotin For Treatment of Patients With Non-muscle Invasive Bladder Cancer (NMIBC)
- Phase
- Phase 1
- Status
- Terminated
- Conditions
- Urinary Bladder Neoplasms; Carcinoma in Situ; Carcinoma Transitional Cell; Non-muscle Invasive Bladder Cancer; NMIBC
- Interventions
- Enfortumab vedotin
- Arms
- Enfortumab vedotin: Dose escalation cohort · Experimental
- Enfortumab vedotin: Dose expansion cohort · Experimental
- Enrollment
- 37
- Primary outcomes
- Incidence of adverse events (AEs)
- Incidence of laboratory abnormalities
- Incidence of dose limiting toxicities (DLTs)
- Sponsor
- Astellas Pharma Global Development, Inc. with Seagen, a wholly owned subsidiary of Pfizer
- Start
- Dec 7, 2021
- Primary completion
- Sep 22, 2025
- Results posted
- No
- Registry record
- NCT05014139 · updated Sep 14, 2026